[
  {
    "ts": "2026-01-14T00:25:19+00:00",
    "headline": "JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions",
    "summary": "Madrigal’s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its brand to MASH treatment.",
    "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-madrigal-seeks-early-dominance-in-mash-through-strategic-acquisitions/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "7ef67d1e-15c9-3391-8222-77aac99c5cba",
      "content": {
        "id": "7ef67d1e-15c9-3391-8222-77aac99c5cba",
        "contentType": "STORY",
        "title": "JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions",
        "description": "",
        "summary": "Madrigal’s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its brand to MASH treatment.",
        "pubDate": "2026-01-14T00:25:19Z",
        "displayTime": "2026-01-14T00:25:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/d2c9274f5695e664713654677740630d",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t9CznWdnwspHj8MmtfRgog--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/d2c9274f5695e664713654677740630d.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nEaOatGr_XKpdmA54Bj9uA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/d2c9274f5695e664713654677740630d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-madrigal-seeks-early-dominance-in-mash-through-strategic-acquisitions/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm26-madrigal-seeks-early-dominance-002519264.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MDGL"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T02:04:44+00:00",
    "headline": "Amneal Pharmaceuticals Eyes 2026 Growth at JPMorgan, Crexont Sales Seen Doubling in 2025",
    "summary": "Amneal Pharmaceuticals (NASDAQ:AMRX) used a presentation and Q&A session at the JPMorgan conference to outline its ongoing shift toward higher-value “affordable medicines” and specialty products, while highlighting near-term growth drivers across complex generics, biosimilars, and branded neurol",
    "url": "https://www.marketbeat.com/instant-alerts/amneal-pharmaceuticals-eyes-2026-growth-at-jpmorgan-crexont-sales-seen-doubling-in-2025-2026-01-13/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "56d1de44-f370-37b6-a283-4b5f579518fb",
      "content": {
        "id": "56d1de44-f370-37b6-a283-4b5f579518fb",
        "contentType": "STORY",
        "title": "Amneal Pharmaceuticals Eyes 2026 Growth at JPMorgan, Crexont Sales Seen Doubling in 2025",
        "description": "",
        "summary": "Amneal Pharmaceuticals (NASDAQ:AMRX) used a presentation and Q&A session at the JPMorgan conference to outline its ongoing shift toward higher-value “affordable medicines” and specialty products, while highlighting near-term growth drivers across complex generics, biosimilars, and branded neurol",
        "pubDate": "2026-01-14T02:04:44Z",
        "displayTime": "2026-01-14T02:04:44Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/ae2eb0de87b5c241b29635b9ec95e87a",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Amneal Pharmaceuticals logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jFulpYr9v8ZnEo4JVHaKiw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/ae2eb0de87b5c241b29635b9ec95e87a.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HlM2YERRMcU3GVpFfFKbPQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/ae2eb0de87b5c241b29635b9ec95e87a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/amneal-pharmaceuticals-eyes-2026-growth-at-jpmorgan-crexont-sales-seen-doubling-in-2025-2026-01-13/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amneal-pharmaceuticals-eyes-2026-growth-020444909.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMRX"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T08:30:00+00:00",
    "headline": "[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global T-Cell Engagers Market size & share revenue was valued at approximately USD 2.4 Billion in 2024 and is expected to reach USD 2.5 Billion in 2025 and is expected to reach around USD 18.8 Billion by 2034, at a CAGR of 21.2% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen, Genmab, Roche/Genentech, Ma",
    "url": "https://finance.yahoo.com/news/latest-global-t-cell-engagers-083000218.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "b15c25b0-c7a0-3818-934e-6ce6fa9019c6",
      "content": {
        "id": "b15c25b0-c7a0-3818-934e-6ce6fa9019c6",
        "contentType": "STORY",
        "title": "[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
        "description": "",
        "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global T-Cell Engagers Market size & share revenue was valued at approximately USD 2.4 Billion in 2024 and is expected to reach USD 2.5 Billion in 2025 and is expected to reach around USD 18.8 Billion by 2034, at a CAGR of 21.2% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen, Genmab, Roche/Genentech, Ma",
        "pubDate": "2026-01-14T08:30:00Z",
        "displayTime": "2026-01-14T08:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891",
          "originalWidth": 2514,
          "originalHeight": 1281,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2CrZC42kgw2SjdY2CY6ucw--~B/aD0xMjgxO3c9MjUxNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891.cf.webp",
              "width": 2514,
              "height": 1281,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/91DUI4_rVm8Et9pJYV6I4Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/latest-global-t-cell-engagers-083000218.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/latest-global-t-cell-engagers-083000218.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "GMAB"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CGEM"
            },
            {
              "symbol": "MGNX"
            },
            {
              "symbol": "XNCR"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T09:04:16+00:00",
    "headline": "BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan",
    "summary": "BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to highlight its transition back toward oncology, outline a slate of upcoming clinical readouts, and discuss how it plans to deploy its cash resources while continuing to fund late-sta",
    "url": "https://www.marketbeat.com/instant-alerts/biontech-pivots-back-to-oncology-at-jpm-conference-teases-15-phase-iii-readouts-and-17b-cash-plan-2026-01-14/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "2498a777-14b3-3e1d-9911-83564122cd1c",
      "content": {
        "id": "2498a777-14b3-3e1d-9911-83564122cd1c",
        "contentType": "STORY",
        "title": "BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan",
        "description": "",
        "summary": "BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to highlight its transition back toward oncology, outline a slate of upcoming clinical readouts, and discuss how it plans to deploy its cash resources while continuing to fund late-sta",
        "pubDate": "2026-01-14T09:04:16Z",
        "displayTime": "2026-01-14T09:04:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/b85d84cdcd3aaa12edbec6fff30e8260",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "BioNTech logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/D6iaAyoB1sh1_P4kFeE2Cw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/b85d84cdcd3aaa12edbec6fff30e8260.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cvdVIEeRlDuMGo0CZSExoA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/b85d84cdcd3aaa12edbec6fff30e8260.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/biontech-pivots-back-to-oncology-at-jpm-conference-teases-15-phase-iii-readouts-and-17b-cash-plan-2026-01-14/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biontech-pivots-back-oncology-jpm-090416406.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BNTX"
            },
            {
              "symbol": "JPM"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]